Recent Company News

• 05:23 PM ET May 31, 2026
  

  Immunocore Holdings presents updated Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma ($28.89, 0.00)

• 02:11 PM ET May 29, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 31-May

• 02:22 PM ET May 22, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 24-May

• 07:15 AM ET May 06, 2026
  

  Immunocore Holdings reports Q1 EPS $0.25 vs FactSet ($0.27) [14 est, ($0.42)-(0.10)] ($28.84, 0.00)

• 06:18 PM ET Apr 19, 2026
  

  Immunocore Holdings presents five-year survival with tebentafusp in previously untreated metastatic uveal melanoma of 16% versus 8% in a Phase 3 trial at AACR 2026 ($31.45, 0.00)

• 03:47 PM ET Apr 13, 2026
  

  Transcript Intelligence: Immunocore Holdings at Needham Virtual Healthcare Conference ($31.54, +0.49)

• 12:07 PM ET Apr 13, 2026
  

  StreetAccount Summary - US unusual volume traders

• 05:38 PM ET Mar 16, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:51 AM ET Mar 16, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:07 PM ET Mar 15, 2026
  

  Jefferies initiates ABVX, DSGN; assumes ALNY, ASND, COGT, others